drugset / Trial / NCT01027260

Study to Evaluate the Role of Itopride HCI in Patients With Irritable Bowel Syndrome With Predominant Constipation

NCT01027260

Phase 2 Completed 268 enrolled Abbott
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Patients suffering from Irritable Bowel Syndrome with predominant constipation will be provided with the study medication. The study medication will be evaluated for its efficacy in relieving the symptoms

Timeline

Start
2008-06
Primary completion
2010-08
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Itopride Small molecule 50 mg
Comparator Itopride Small molecule 100 mg